Anders Nykjaer

Founder at Insusense ApS

Health Technology

Miscellaneous

Consumer Services

Active connections

Name	Gender	Age	Linked companies	Collaboration
Mads Fuglsang Kjølby	M	-	Insusense ApS Insusense ApS BiotechnologyHealth Technology Insusense ApS provides research and development in biotechnology. It conducts research and development on new medicines for treatment of diabetes, diabetes related diseases, and obesity. The company was founded by Anders Nykjær on April 19, 2010 and is headquartered in Copenhagen, Denmark.	-
Paul B. Little	M	-	Insusense ApS Insusense ApS BiotechnologyHealth Technology Insusense ApS provides research and development in biotechnology. It conducts research and development on new medicines for treatment of diabetes, diabetes related diseases, and obesity. The company was founded by Anders Nykjær on April 19, 2010 and is headquartered in Copenhagen, Denmark.	20 years
Karl Anker Jørgensen	M	69	University of Aarhus	-
Connie Hedegaard Koksbang	F	63	University of Aarhus	7 years
Lars Henrik Fugger	M	64	University of Aarhus	28 years
Michael Christiansen	M	79	University of Aarhus	-
Finn Skou Pedersen	M	-	University of Aarhus	-
Mogens Ryttergård Duch	M	-	University of Aarhus	-
Karl Møller Bek	M	-	University of Aarhus	-
Sara Fevre Kindberg	M	-	University of Aarhus	-
Jesper Zeuthen	M	-	University of Aarhus	-
Jon Steen Petersen	M	77	University of Aarhus	-
Claus Vastrup	M	82	University of Aarhus	-
Børge Obel	M	76	University of Aarhus	20 years
Jens Christian Jensenius	M	82	University of Aarhus	-
Henrik Kagenow	M	-	University of Aarhus	-
Peder Tuborgh	M	61	University of Aarhus	-
Brian Bech Nielsen	M	66	University of Aarhus	36 years
Carsten Bjerg	M	64	University of Aarhus	-
Nina Smith	F	68	University of Aarhus	-
Caroline Søeborg Ahlefeldt-Laurvig-Bille	F	-	University of Aarhus	5 years

Connections Chart

Multi-company connection

Former connections

Name	Gender	Age	Linked companies	Collaboration
Thomas E. Willnow	M	-	Recepticon ApS Recepticon ApS Pharmaceuticals: MajorHealth Technology ReceptIcon is a biotech company based on the identification of novel receptors in the kidney that are responsible for renal uptake and nephrotoxity of therapeutic drugs. The company is focused on the development of receptor antagonists that prevent accumulation of therapeutics in the kidney. Such antagonists can be used as active pharmaceutical ingredients for reformulation of marketed nephrotoxic drugs thereby precluding their toxic side effects.	9 years
Henrik Andersen	M	56	University of Aarhus	9 years
Gian Luca Cattani	M	55	University of Aarhus	4 years
Rune Róin	M	-	University of Aarhus	5 years
Karsten Breum	M	51	University of Aarhus	4 years
Mikael Andreas Geday	M	56	University of Aarhus	7 years
Dorthe Berntsen	M	62	University of Aarhus	5 years
Martin Lippert	M	57	University of Aarhus	5 years
Jim Snabe	M	58	University of Aarhus	6 years
Etienne Adriansen	M	60	University of Aarhus	5 years
Kristian Villumsen	M	54	University of Aarhus	1 years
Poul Jagd Mogensen	M	-	University of Aarhus	3 years
Jørgen Rønnow	M	-	University of Aarhus	1 years
Lucy Lu Li Dahlgren	F	55	University of Aarhus	4 years
Anders Lund	M	51	University of Aarhus	4 years
Erik Dudman Nielsen	M	-	University of Aarhus	1 years
Peter Baekgaard	M	-	University of Aarhus	5 years
Line Christa Amanda Sørensen	F	49	University of Aarhus	3 years
Thomas Dalsgaard	M	58	University of Aarhus	6 years
Jesper Ejlersen	M	57	University of Aarhus	1 years
Merete Vangsøe Simonsen	F	57	University of Aarhus	3 years
Otto Frederik Spliid	M	63	University of Aarhus	3 years
Carsten Fensholt	M	62	University of Aarhus	4 years
Kurt Bligaard Pedersen	M	65	University of Aarhus	1 years
Marina Lønning	F	56	University of Aarhus	1 years
John Petersen	M	-	University of Aarhus	6 years
Dorte Wigg	F	-	University of Aarhus	3 years
Anders Svenningsen	M	-	University of Aarhus	6 years
John Sommer Schmidt	M	51	University of Aarhus	4 years
Tina Høgsted Svanberg	F	-	University of Aarhus	4 years
Mogens Thorninger	M	-	University of Aarhus	5 years
Tommy Jensen	M	-	University of Aarhus	2 years
Marianne Søgaard	F	56	University of Aarhus	3 years
Ulrik Thagesen	M	53	University of Aarhus	1 years
Michael Hannibal	M	55	University of Aarhus	3 years
Casper Blaase Johansen	M	49	University of Aarhus	4 years
Preben Vinkler Lindgaard	M	56	University of Aarhus	1 years
Stenkil Ole	M	51	University of Aarhus	5 years
Ricco Larsen	M	-	University of Aarhus	6 years
Søren Elmann Ingerslev	M	-	University of Aarhus	3 years
Milan Zdravkovic	M	54	University of Aarhus	7 years
Morten Kierkegaard	M	54	University of Aarhus	1 years
Lars Green	M	57	University of Aarhus	1 years
Ulf Roger Tossman	M	68	Recepticon ApS Recepticon ApS Pharmaceuticals: MajorHealth Technology ReceptIcon is a biotech company based on the identification of novel receptors in the kidney that are responsible for renal uptake and nephrotoxity of therapeutic drugs. The company is focused on the development of receptor antagonists that prevent accumulation of therapeutics in the kidney. Such antagonists can be used as active pharmaceutical ingredients for reformulation of marketed nephrotoxic drugs thereby precluding their toxic side effects.	-
Jørn Enggaard	M	-	Recepticon ApS Recepticon ApS Pharmaceuticals: MajorHealth Technology ReceptIcon is a biotech company based on the identification of novel receptors in the kidney that are responsible for renal uptake and nephrotoxity of therapeutic drugs. The company is focused on the development of receptor antagonists that prevent accumulation of therapeutics in the kidney. Such antagonists can be used as active pharmaceutical ingredients for reformulation of marketed nephrotoxic drugs thereby precluding their toxic side effects.	-
Klaus Pedersen	M	57	University of Aarhus	1 years
Palle Schelde Jensen	M	-	Recepticon ApS Recepticon ApS Pharmaceuticals: MajorHealth Technology ReceptIcon is a biotech company based on the identification of novel receptors in the kidney that are responsible for renal uptake and nephrotoxity of therapeutic drugs. The company is focused on the development of receptor antagonists that prevent accumulation of therapeutics in the kidney. Such antagonists can be used as active pharmaceutical ingredients for reformulation of marketed nephrotoxic drugs thereby precluding their toxic side effects.	-
Alex Haahr Gouliaev	M	58	University of Aarhus	3 years
Mads Nipper	M	58	University of Aarhus	2 years
Hans-Henrik Horsted Eriksen	M	64	Recepticon ApS Recepticon ApS Pharmaceuticals: MajorHealth Technology ReceptIcon is a biotech company based on the identification of novel receptors in the kidney that are responsible for renal uptake and nephrotoxity of therapeutic drugs. The company is focused on the development of receptor antagonists that prevent accumulation of therapeutics in the kidney. Such antagonists can be used as active pharmaceutical ingredients for reformulation of marketed nephrotoxic drugs thereby precluding their toxic side effects.	-
Steen Helde Hemmingsen	M	80	Recepticon ApS Recepticon ApS Pharmaceuticals: MajorHealth Technology ReceptIcon is a biotech company based on the identification of novel receptors in the kidney that are responsible for renal uptake and nephrotoxity of therapeutic drugs. The company is focused on the development of receptor antagonists that prevent accumulation of therapeutics in the kidney. Such antagonists can be used as active pharmaceutical ingredients for reformulation of marketed nephrotoxic drugs thereby precluding their toxic side effects.	-
Morten Brøgger	M	55	University of Aarhus	1 years
Kristian Johnsen Hundebøll	M	58	University of Aarhus	4 years
Kaare Heinsen	M	-	University of Aarhus	4 years
Jørgen Jensen	M	56	University of Aarhus	1 years
Mikael Vissing Jakobsen	M	-	University of Aarhus	4 years
Torbjørn Bjerke	M	61	University of Aarhus	6 years
Hans Jacob Carstensen	M	59	University of Aarhus	2 years
René Schneider	M	51	University of Aarhus	6 years
Anders Pedersen	M	64	Recepticon ApS Recepticon ApS Pharmaceuticals: MajorHealth Technology ReceptIcon is a biotech company based on the identification of novel receptors in the kidney that are responsible for renal uptake and nephrotoxity of therapeutic drugs. The company is focused on the development of receptor antagonists that prevent accumulation of therapeutics in the kidney. Such antagonists can be used as active pharmaceutical ingredients for reformulation of marketed nephrotoxic drugs thereby precluding their toxic side effects.	3 years
Flemming Besenbacher	M	71	University of Aarhus	3 years
Jan Anders Vedin	M	82	Recepticon ApS Recepticon ApS Pharmaceuticals: MajorHealth Technology ReceptIcon is a biotech company based on the identification of novel receptors in the kidney that are responsible for renal uptake and nephrotoxity of therapeutic drugs. The company is focused on the development of receptor antagonists that prevent accumulation of therapeutics in the kidney. Such antagonists can be used as active pharmaceutical ingredients for reformulation of marketed nephrotoxic drugs thereby precluding their toxic side effects.	-
Henrik Nørremark	M	58	University of Aarhus	4 years
Henrik Poulsen	M	57	University of Aarhus	1 years
Lars Fruergaard Jorgensen	M	58	University of Aarhus	1 years
Allan Viggo Tornøe Nørholm	M	58	University of Aarhus	1 years
Henriette Schütze	F	56	University of Aarhus	1 years
Søren Steen Pedersen	M	-	University of Aarhus	2 years
Holger Jon Møller	M	-	University of Aarhus	3 years
Jørgen Michael Christensen	M	74	University of Aarhus	3 years
Ole Christian Anthon Christiansen	M	67	University of Aarhus	1 years
Jakob Bardram	M	56	University of Aarhus	3 years
Louis Illum Honoré	M	62	University of Aarhus	4 years
Henrik Dalbøge	M	67	University of Aarhus	3 years
Niels Hobolt	M	-	University of Aarhus	1 years
Carsten Tirsbæk Madsen	M	61	University of Aarhus	1 years
Steffen B. Petersen	M	-	University of Aarhus	5 years
Peter Marner Åge Jacobsen	M	61	University of Aarhus	1 years
Lars Lose	M	-	University of Aarhus	6 years

Statistics

Country	Connections	% of total
Denmark	100	100.00%

Age of Connections

Active

Past

Male

Female

Members of the board

Executives

Origin of connections